​

Monte Rosa Therapeutics (GLUE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GLUE Stock Rating

Monte Rosa Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

GLUE Price Target Upside V Benchmarks

TypeNameUpside
StockMonte Rosa Therapeutics-
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$4.41$4.41$4.41
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25261--9
Mar, 25251--8
Feb, 25251--8
Jan, 25251--8
Dec, 24261--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2024Cowen & Co.BuyBuyhold
Oct 28, 2024Piper SandlerOverweightOverweighthold
Aug 12, 2024Wells FargoOverweightOverweighthold
Jun 28, 2024Cowen & Co.BuyBuyhold
Jun 28, 2024Piper SandlerOverweightOverweighthold
May 30, 2024Piper SandlerOverweightOverweighthold
Feb 15, 2024WedbushOutperforminitialise
Jan 03, 2023Wells FargoOverweightupgrade
Apr 28, 2022Credit SuisseNeutralinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.63$-0.98----
Avg Forecast$-2.40$-1.01$-1.55$-1.95$-1.87$-0.51
High Forecast$-2.09$-0.97$-0.96$-0.98$-0.31$-0.11
Low Forecast$-2.55$-1.07$-2.05$-3.67$-3.57$-0.87
Surprise %9.58%-2.97%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$75.62M----
Avg Forecast$3.53M$66.18M$24.18M$25.96M$86.61M$253.19M
High Forecast$5.49M$82.03M$37.66M$26.74M$134.90M$394.36M
Low Forecast$1.41M$47.62M$9.68M$25.18M$34.68M$101.38M
Surprise %-14.26%----

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-135.35M$-72.70M----
Avg Forecast$-119.20M$-52.24M$-77.46M$-179.28M$-99.78M$-26.04M
High Forecast$-107.23M$-49.64M$-49.57M$-50.50M$-16.17M$-5.74M
Low Forecast$-131.17M$-54.84M$-105.34M$-188.47M$-183.39M$-44.92M
Surprise %13.55%39.17%----

GLUE Forecast FAQ

Is Monte Rosa Therapeutics stock a buy?

Monte Rosa Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Monte Rosa Therapeutics is a favorable investment for most analysts.

What is Monte Rosa Therapeutics's price target?

Monte Rosa Therapeutics's price target, set by 7 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $4.41.

How does Monte Rosa Therapeutics stock forecast compare to its benchmarks?

Monte Rosa Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Monte Rosa Therapeutics over the past three months?

  • April 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Monte Rosa Therapeutics’s EPS forecast?

Monte Rosa Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.55, marking a 58.16% increase from the reported $-0.98 in 2024. Estimates for the following years are $-1.95 in 2026, $-1.87 in 2027, and $-0.51 in 2028.

What is Monte Rosa Therapeutics’s revenue forecast?

Monte Rosa Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $24.18M, reflecting a -68.02% decrease from the reported $75.62M in 2024. The forecast for 2026 is $25.96M, followed by $86.61M for 2027, and $253.19M for 2028.

What is Monte Rosa Therapeutics’s net income forecast?

Monte Rosa Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-77.457M, representing an 6.54% increase from the reported $-72.7M in 2024. Projections indicate $-179M in 2026, $-99.779M in 2027, and $-26.041M in 2028.